Scientists have developed a way to deliver a nerve-protecting substance past the brain’s natural defenses using fat-based ‘bubbles,’ a strategy that significantly extended survival and preserved movement in mouse models of amyotrophic lateral sclerosis (ALS). This approach, called talineuren, successfully delivered the protective molecule GM1 directly to damaged motor…
News
Dosing has begun in a new arm of the HEALEY ALS platform trial, with Regimen I — the ninth — testing NUZ-001, an oral small molecule developed by Neurizon Therapeutics to slow declines in function and extend survival in people with amyotrophic lateral sclerosis (ALS). As a platform…
Next week, researchers, clinicians, industry leaders, and families will gather at the 2026 MDA Clinical & Scientific Conference, hosted by the Muscular Dystrophy Association (MDA), to discuss the latest advances in neuromuscular disease research and care. Ahead of the event, Bionews, the parent company of this site, sat…
Blood levels of lactate — a molecule involved in how the body produces energy — may help predict survival and short-term weight changes in people with amyotrophic lateral sclerosis (ALS), according to a new study from Australia and Japan. Researchers found that patients with lower blood lactate levels had…
AB Science has identified a new blood biomarker, produced by certain immune cells, that may help assess the activity of its experimental therapy masitinib in people with amyotrophic lateral sclerosis (ALS). The biomarker, which the company did not disclose for patent protection reasons, is capable of identifying patients…
Early birds — people with a natural tendency to wake up and go to sleep at earlier times — are significantly less likely to develop amyotrophic lateral sclerosis (ALS) than night owls, whose natural preference is to wake up and go to sleep at later times, according to a…
The experimental therapy QRL-201 successfully reached its biological target and showed early signs that it may slow disease progression in people with sporadic amyotrophic lateral sclerosis (ALS), according to new Phase 1/2 trial data. These interim results from the proof-of-concept ANQUR trial (NCT05633459) suggest the treatment can…
The Muscular Dystrophy Association (MDA) has launched its annual MDA Shamrocks campaign, described as the nation’s largest St. Patrick’s Day-themed fundraiser, to support people living with amyotrophic lateral sclerosis (ALS) and other rare neuromuscular diseases. During the campaign, held throughout February and March, thousands of retailers across the…
An assistant professor from the University of Nevada, Las Vegas, whose work focuses on the molecular mechanisms underlying amyotrophic lateral sclerosis (ALS), has been named the first recipient of the MDA Research Momentum Award, a new honor from the Muscular Dystrophy Association (MDA) for early-career scientists. According to an MDA…
Early treatment with PrimeC, an experimental oral treatment being developed by Neurosense Therapeutics, significantly extended survival in people with amyotrophic lateral sclerosis (ALS) by more than 14 months compared with a six-month delay in treatment initiation. That’s according to additional long-term data from PARADIGM (NCT05357950), a completed…
Recent Posts
- Learning ALS self-advocacy involves being a little pushy
- Brain implant decodes finger moves so paralyzed patients can type
- Grant funds new ALS treatment approach targeting TDP-43 pathway
- Amydis awarded $2.5M to develop diagnostic eye test for ALS
- Mourning the loss of a leader, friend, and advocate for women with ALS